Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Cameron's Law (HR 1414) EPIC Act (HR 1492/S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
S. 3019 - No Big Blockbuster Bailouts Act (NOBBBA) Cameron's Law (HR 1414) EPIC Act (HR 1492, S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2026 · third_quarter · Q3
S. 3019 - No Big Blockbuster Bailouts Act (NOBBBA) Cameron's Law (HR 1414) EPIC Act (HR 1492, S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2026 · second_quarter · Q2
Source: Senate LDA
S. 3019 - No Big Blockbuster Bailouts Act (NOBBBA) Cameron's Law (HR 1414) EPIC Act (HR 1492, S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
S. 3019 - No Big Blockbuster Bailouts Act (NOBBBA) Cameron's Law (HR 1414) EPIC Act (HR 1492, S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
S. 3019 - No Big Blockbuster Bailouts Act (NOBBBA) Cameron's Law (HR 1414) EPIC Act (HR 1492, S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Cameron's Law (HR 1414) EPIC Act (HR 1492/S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
Maintaining Investments in New Innovation Act
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
S. 3019 - No Big Blockbuster Bailouts Act (NOBBBA) Cameron's Law (HR 1414) EPIC Act (HR 1492, S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
Maintaining Investments in New Innovation Act
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
S. 3019 - No Big Blockbuster Bailouts Act (NOBBBA) Cameron's Law (HR 1414) EPIC Act (HR 1492, S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
Maintaining Investments in New Innovation Act
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Cameron's Law (HR 1414) EPIC Act (HR 1492/S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
S. 3019 - No Big Blockbuster Bailouts Act (NOBBBA) Cameron's Law (HR 1414) EPIC Act (HR 1492, S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
S. 3019 - No Big Blockbuster Bailouts Act (NOBBBA) Cameron's Law (HR 1414) EPIC Act (HR 1492, S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
Cameron's Law (HR 1414) EPIC Act (HR 1492/S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
S. 3019 - No Big Blockbuster Bailouts Act (NOBBBA) Cameron's Law (HR 1414) EPIC Act (HR 1492, S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
S. 3019 - No Big Blockbuster Bailouts Act (NOBBBA) Cameron's Law (HR 1414) EPIC Act (HR 1492, S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
Mikaela Naylon Give Kids a Chance Act
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
Mikaela Naylon Give Kids a Chance Act
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
HR 946/ S 1862 ORPHAN Cures Act S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
Mikaela Naylon Give Kids a Chance Act
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
Maintaining Investments in New Innovation Act
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
Maintaining Investments in New Innovation Act
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
HR 946/ S 1862 ORPHAN Cures Act S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
Maintaining Investments in New Innovation Act
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
HR 946/ S 1862 ORPHAN Cures Act S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
HR 946/ S 1862 ORPHAN Cures Act S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
Innovation in Pediatric Drugs Act of 2025
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
Innovation in Pediatric Drugs Act of 2025
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
HR 946/ S 1862 ORPHAN Cures Act S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
Innovation in Pediatric Drugs Act of 2025
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
HR 946/ S 1862 ORPHAN Cures Act S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
HR 946/ S 1862 ORPHAN Cures Act S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
H.R. 5547, Maintaining Investments in New Innovation (MINI) Act (118th Congress) H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act (118th Congress) H.R. 6094, Providing Realistic Opportunity To Equal and Comparable Treatment for (PROTECT) Rare Act (118th Congress) H.R. 6664, Innovation in Pediatric Drugs Act (118th Congress) H.R. 7384, Creating Hope Reauthorization Act (118th Congress) H.R. 7383, Retaining Access and Restoring Exclusivity (RARE) Act (118th Congress) H.R.7024, Tax Relief for American Families and Workers Act of 2024 (118th Congress) H.R.3433 / S.2897, Give Kids a Chance Act (118th Congress)
H.R. 5547, Maintaining Investments in New Innovation (MINI) Act (118th Congress) H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act (118th Congress) H.R. 6094, Providing Realistic Opportunity To Equal and Comparable Treatment for (PROTECT) Rare Act (118th Congress) H.R. 6664, Innovation in Pediatric Drugs Act (118th Congress) H.R. 7384, Creating Hope Reauthorization Act (118th Congress) H.R. 7383, Retaining Access and Restoring Exclusivity (RARE) Act (118th Congress) H.R.7024, Tax Relief for American Families and Workers Act of 2024 (118th Congress) H.R.3433 / S.2897, Give Kids a Chance Act (118th Congress)
Maintaining Investments in New Innovation Act
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
H.R. 5547, Maintaining Investments in New Innovation (MINI) Act (118th Congress) H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act (118th Congress) H.R. 6094, Providing Realistic Opportunity To Equal and Comparable Treatment for (PROTECT) Rare Act (118th Congress) H.R. 6664, Innovation in Pediatric Drugs Act (118th Congress) H.R. 7384, Creating Hope Reauthorization Act (118th Congress) H.R. 7383, Retaining Access and Restoring Exclusivity (RARE) Act (118th Congress) H.R.7024, Tax Relief for American Families and Workers Act of 2024 (118th Congress) H.R.3433 / S.2897, Give Kids a Chance Act (118th Congress)
Providing Realistic Opportunity To Equal and Comparable Treatment for Rare Act
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
H.R. 5547, Maintaining Investments in New Innovation (MINI) Act (118th Congress) H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act (118th Congress) H.R. 6094, Providing Realistic Opportunity To Equal and Comparable Treatment for (PROTECT) Rare Act (118th Congress) H.R. 6664, Innovation in Pediatric Drugs Act (118th Congress) H.R. 7384, Creating Hope Reauthorization Act (118th Congress) H.R. 7383, Retaining Access and Restoring Exclusivity (RARE) Act (118th Congress) H.R.7024, Tax Relief for American Families and Workers Act of 2024 (118th Congress) H.R.3433 / S.2897, Give Kids a Chance Act (118th Congress)
Innovation in Pediatric Drugs Act of 2023
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
H.R. 5547, Maintaining Investments in New Innovation (MINI) Act (118th Congress) H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act (118th Congress) H.R. 6094, Providing Realistic Opportunity To Equal and Comparable Treatment for (PROTECT) Rare Act (118th Congress) H.R. 6664, Innovation in Pediatric Drugs Act (118th Congress) H.R. 7384, Creating Hope Reauthorization Act (118th Congress) H.R. 7383, Retaining Access and Restoring Exclusivity (RARE) Act (118th Congress) H.R.7024, Tax Relief for American Families and Workers Act of 2024 (118th Congress) H.R.3433 / S.2897, Give Kids a Chance Act (118th Congress)
Tax Relief for American Families and Workers Act of 2024
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
H.R. 5547, Maintaining Investments in New Innovation (MINI) Act (118th Congress) H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act (118th Congress) H.R. 6094, Providing Realistic Opportunity To Equal and Comparable Treatment for (PROTECT) Rare Act (118th Congress) H.R. 6664, Innovation in Pediatric Drugs Act (118th Congress) H.R. 7384, Creating Hope Reauthorization Act (118th Congress) H.R. 7383, Retaining Access and Restoring Exclusivity (RARE) Act (118th Congress) H.R.7024, Tax Relief for American Families and Workers Act of 2024 (118th Congress) H.R.3433 / S.2897, Give Kids a Chance Act (118th Congress)
H.R. 5547, Maintaining Investments in New Innovation (MINI) Act (118th Congress) H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act (118th Congress) H.R. 6094, Providing Realistic Opportunity To Equal and Comparable Treatment for (PROTECT) Rare Act (118th Congress) H.R. 6664, Innovation in Pediatric Drugs Act (118th Congress) H.R. 7384, Creating Hope Reauthorization Act (118th Congress) H.R. 7383, Retaining Access and Restoring Exclusivity (RARE) Act (118th Congress) H.R.7024, Tax Relief for American Families and Workers Act of 2024 (118th Congress) H.R.3433 / S.2897, Give Kids a Chance Act (118th Congress)
Creating Hope Reauthorization Act of 2024
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
H.R. 5547, Maintaining Investments in New Innovation (MINI) Act (118th Congress) H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act (118th Congress) H.R. 6094, Providing Realistic Opportunity To Equal and Comparable Treatment for (PROTECT) Rare Act (118th Congress) H.R. 6664, Innovation in Pediatric Drugs Act (118th Congress) H.R. 7384, Creating Hope Reauthorization Act (118th Congress) H.R. 7383, Retaining Access and Restoring Exclusivity (RARE) Act (118th Congress) H.R.7024, Tax Relief for American Families and Workers Act of 2024 (118th Congress) H.R.3433 / S.2897, Give Kids a Chance Act (118th Congress)
H.R. 5547, Maintaining Investments in New Innovation (MINI) Act (118th Congress) H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act (118th Congress) H.R. 6094, Providing Realistic Opportunity To Equal and Comparable Treatment for (PROTECT) Rare Act (118th Congress) H.R. 6664, Innovation in Pediatric Drugs Act (118th Congress) H.R. 7384, Creating Hope Reauthorization Act (118th Congress) H.R. 7383, Retaining Access and Restoring Exclusivity (RARE) Act (118th Congress) H.R.7024, Tax Relief for American Families and Workers Act of 2024 (118th Congress) H.R.3433 / S.2897, Give Kids a Chance Act (118th Congress)
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, Leos Law.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, The Rare Disease Clinical Trials Pandemic Disruption Act. Reauthorization of the Pandemic and All-Hazards Preparedness Act.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, The Rare Disease Clinical Trials Pandemic Disruption Act. Reauthorization of the Pandemic and All-Hazards Preparedness Act.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, Leos Law.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act.
American Innovation and R&D Competitiveness Act of 2023
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to Medicare Part D redesign. H.R. 2673, The American Innovation and R&D Competitiveness Act.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act.
Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R. 830, S.1375, The HELP Copays Act
Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R. 830, S.1375, The HELP Copays Act
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act.
Speeding Therapy Access Today Act of 2021
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Speeding Therapy Access Today Act of 2021
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Speeding Therapy Access Today Act of 2021
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Elijah E. Cummings Lower Drug Costs Now Act
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
- Issues related to the development of therapies for rare diseases. - H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; - H.R.6000, Cures 2.0 Act; - FY2022 Budget Reconciliation (H.R.5376); - H.R.5585, Advanced Research Project Agency-Health Act; - H.R.6963, Accelerated Approval Integrity Act of 2022; - H.R.7667, Food and Drug Amendments of 2022; - S.4348, FDASLA Act of 2022 - Issues relative to formulary placement of non-scheduled treatments
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
- Issues related to the development of therapies for rare diseases. - H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; - H.R.6000, Cures 2.0 Act; - FY2022 Budget Reconciliation (H.R.5376); - H.R.5585, Advanced Research Project Agency-Health Act; - H.R.6963, Accelerated Approval Integrity Act of 2022; - H.R.7667, Food and Drug Amendments of 2022; - S.4348, FDASLA Act of 2022 - Issues relative to formulary placement of non-scheduled treatments
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
- Issues related to the development of therapies for rare diseases. - Build Back Better Act (H.R. 5376) - CURES 2.0 Act (H.R. 6000) - FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376)
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
- Issues related to the development of therapies for rare diseases. - H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; - H.R.6000, Cures 2.0 Act; - FY2022 Budget Reconciliation (H.R.5376); - H.R.5585, Advanced Research Project Agency-Health Act; - H.R.6963, Accelerated Approval Integrity Act of 2022; - H.R.7667, Food and Drug Amendments of 2022; - S.4348, FDASLA Act of 2022 - Issues relative to formulary placement of non-scheduled treatments
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
- Issues related to the development of therapies for rare diseases. - H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; - H.R.6000, Cures 2.0 Act; - FY2022 Budget Reconciliation (H.R.5376); - H.R.5585, Advanced Research Project Agency-Health Act; - H.R.6963, Accelerated Approval Integrity Act of 2022; - H.R.7667, Food and Drug Amendments of 2022; - S.4348, FDASLA Act of 2022 - Issues relative to formulary placement of non-scheduled treatments
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
- Issues related to the development of therapies for rare diseases. - Build Back Better Act (H.R. 5376) - CURES 2.0 Act (H.R. 6000) - FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376)
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Accelerated Approval Integrity Act of 2022
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
- Issues related to the development of therapies for rare diseases. - H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; - H.R.6000, Cures 2.0 Act; - FY2022 Budget Reconciliation (H.R.5376); - H.R.5585, Advanced Research Project Agency-Health Act; - H.R.6963, Accelerated Approval Integrity Act of 2022; - H.R.7667, Food and Drug Amendments of 2022; - S.4348, FDASLA Act of 2022 - Issues relative to formulary placement of non-scheduled treatments
Accelerated Approval Integrity Act of 2022
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Accelerated Approval Integrity Act of 2022
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Accelerated Approval Integrity Act of 2022
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
- Issues related to the development of therapies for rare diseases. - H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; - H.R.6000, Cures 2.0 Act; - FY2022 Budget Reconciliation (H.R.5376); - H.R.5585, Advanced Research Project Agency-Health Act; - H.R.6963, Accelerated Approval Integrity Act of 2022; - H.R.7667, Food and Drug Amendments of 2022; - S.4348, FDASLA Act of 2022 - Issues relative to formulary placement of non-scheduled treatments
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Orphan Drug COVID–19 Mitigation Act of 2022
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Orphan Drug COVID–19 Mitigation Act of 2022
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Orphan Drug COVID–19 Mitigation Act of 2022
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
- Issues related to the development of therapies for rare diseases. - H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; - H.R.6000, Cures 2.0 Act; - FY2022 Budget Reconciliation (H.R.5376); - H.R.5585, Advanced Research Project Agency-Health Act; - H.R.6963, Accelerated Approval Integrity Act of 2022; - H.R.7667, Food and Drug Amendments of 2022; - S.4348, FDASLA Act of 2022 - Issues relative to formulary placement of non-scheduled treatments
Speeding Therapy Access Today Act of 2021
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Speeding Therapy Access Today Act of 2021
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Speeding Therapy Access Today Act of 2021
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: HARMONY BIOSCIENCES · Firm: HARMONY BIOSCIENCES
- Issues related to the development of therapies for rare diseases. - Build Back Better Act (H.R. 5376) - CURES 2.0 Act (H.R. 6000) - FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376)
S. 3019 - No Big Blockbuster Bailouts Act (NOBBBA) Cameron's Law (HR 1414) EPIC Act (HR 1492, S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2026 · first_quarter · Q1
Cameron's Law (HR 1414) EPIC Act (HR 1492/S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2025 · fourth_quarter · Q4
S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2025 · third_quarter · Q3
S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2025 · second_quarter · Q2
HR 946/ S 1862 ORPHAN Cures Act S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2025 · first_quarter · Q1
H.R. 5547, Maintaining Investments in New Innovation (MINI) Act (118th Congress) H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act (118th Congress) H.R. 6094, Providing Realistic Opportunity To Equal and Comparable Treatment for (PROTECT) Rare Act (118th Congress) H.R. 6664, Innovation in Pediatric Drugs Act (118th Congress) H.R. 7384, Creating Hope Reauthorization Act (118th Congress) H.R. 7383, Retaining Access and Restoring Exclusivity (RARE) Act (118th Congress) H.R.7024, Tax Relief for American Families and Workers Act of 2024 (118th Congress) H.R.3433 / S.2897, Give Kids a Chance Act (118th Congress)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2024 · first_quarter · Q1
Issues related to the development and approval of rare disease treatments
Issues related to the development and approval of rare disease treatments
Issues related to the development and approval of rare disease treatments
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2023 · fourth_quarter · Q4
Issues related to the development and approval of rare disease treatments
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2023 · third_quarter · Q3
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2023 · second_quarter · Q2
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, Leos Law.
Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R. 830, S.1375, The HELP Copays Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2023 · first_quarter · Q1
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, The Rare Disease Clinical Trials Pandemic Disruption Act. Reauthorization of the Pandemic and All-Hazards Preparedness Act.
Issues related to Medicare Part D redesign. H.R. 2673, The American Innovation and R&D Competitiveness Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2022 · fourth_quarter · 4A
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2022 · fourth_quarter · Q4
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2022 · third_quarter · Q3
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2022 · second_quarter · Q2
- Issues related to the development of therapies for rare diseases. - H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; - H.R.6000, Cures 2.0 Act; - FY2022 Budget Reconciliation (H.R.5376); - H.R.5585, Advanced Research Project Agency-Health Act; - H.R.6963, Accelerated Approval Integrity Act of 2022; - H.R.7667, Food and Drug Amendments of 2022; - S.4348, FDASLA Act of 2022 - Issues relative to formulary placement of non-scheduled treatments
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2022 · first_quarter · Q1
- Issues related to the development of therapies for rare diseases. - Build Back Better Act (H.R. 5376) - CURES 2.0 Act (H.R. 6000) - FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2021 · fourth_quarter · Q4
- Issues related to the development of therapies for rare diseases. - Build Back Better Act (H.R. 5376) - CURES 2.0 Act (H.R. 6000) - FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2021 · third_quarter · Q3
- Issues related to the development of therapies for rare diseases. - H.R. 3 Lower Drug Costs Now Act - CURES 2.0 Act discussion draft - FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2021 · second_quarter · Q2
- Issues related to the development of therapies for rare diseases. - H.R. 3 Lower Drug Costs Now Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2021 · first_quarter · Q1
Issues related to the development of therapies for rare diseases.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2020 · fourth_quarter · Q4
Issues related to the development of therapies for rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2020 · third_quarter · Q3
Issues related to the development of therapies for rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2020 · second_quarter · Q2
Issues related to the development of therapies for rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2020 · first_quarter · Q1
Issues related to the development of therapies for rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2019 · fourth_quarter · Q4
Issues related to the development of therapies for rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2019 · third_quarter · Q3
Issues related to the development of therapies for rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, Office of Natl Drug Control Policy (NDCP), SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2019 · second_quarter · Q2
Issues related to the development of therapies for rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, Office of Natl Drug Control Policy (NDCP), SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2019 · first_quarter · Q1
Issues related to the development of therapies for rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via HARMONY BIOSCIENCES
2019 · first_quarter · RR
Access to medication, research in sleep disorders
Access to medication, research in sleep disorders
Access to medication, research in sleep disorders
Issues related to the development and approval of rare disease treatments
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE